Breaking News Instant updates and real-time market news.

BLUE

bluebird bio

$131.50

3.75 (2.94%)

, CRSP

Crispr Therapeutics

$19.70

0.4 (2.07%)

04:55
10/10/17
10/10
04:55
10/10/17
04:55

Chardan to hold a conference

2017 Inaugural Gene Therapy Conference is being held in New York on October 10.

BLUE

bluebird bio

$131.50

3.75 (2.94%)

CRSP

Crispr Therapeutics

$19.70

0.4 (2.07%)

ARWR

Arrowhead

$4.36

0.11 (2.59%)

AGTC

Applied Genetic

$4.05

0.05 (1.25%)

VBLT

VBL Therapeutics

$5.95

0.15 (2.59%)

MGEN

Miragen Therapeutics

$9.34

-0.1 (-1.06%)

  • 10

    Oct

  • 06

    Nov

BLUE bluebird bio
$131.50

3.75 (2.94%)

10/03/17
WELS
10/03/17
NO CHANGE
WELS
Outperform
bluebird bio should be bought on weakness, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on shares of bluebird bio and recommends buying on weakness, following a call with management and what he believes to be flawed competitor analysis related to the companies LentiGlobin gene therapy program for Sickle Cell Disease. With concerns raised regarding correlation between ex vivo drug product vector copy number and in vivo peripheral vector copy number, the analyst believes that pooling of small patient numbers, from different studies, not consistently exposed to the same gene therapy product or transplant protocol, provides inadequate framework for correlation analysis and conclusion on prospects for clinical success in Sickle Cell Disease. Importantly, Birchenough argues that at the current bluebird bio share price of $120/share, only $16/share is attributable to Sickle Cell Disease, with an implied likelihood of success of only 10%, and that base value of $104/share can be supported by BCMA CAR-T, LentiGlobin for Beta Thalassemia, and gene therapy for adrenoleukodystrophy.
10/02/17
10/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Hold from Buy at Jefferies with analyst Kevin Grundy saying North American beverage trends continue to deteriorate and Pepsi's likely need for reinvestment should "cap the stock" over the next 12 months. 2. Western Digital (WDC) downgraded to Neutral from Outperform at Baird with analyst Tristan Gerra saying he believes the potential outcomes from the company's ongoing litigation with Toshiba (TOSYY) "range from neutral to significantly negative" and the ongoing fight will cap the stock's valuation in the near-term. 3. Uniti Group (UNIT) downgraded to Neutral from Overweight at JPMorgan with analyst Philip Cusick saying the "theme of Windstream's (WIN) distress continues to increase in volume." 4. Parker-Hannifin (PH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Nigel Coe saying he sees a more balanced risk-reward following the stock's strong outperformance since the election. 5. bluebird bio (BLUE) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Matthew Harrison saying he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
10/02/17
DOWNGRADE
Target $105

Underweight
bluebird bio downgraded to Underweight on sickle cell risk at Morgan Stanley
As previously reported, Morgan Stanley analyst Matthew Harrison downgraded bluebird bio (BLUE) to Underweight from Equal Weight, as he believes the risks ahead of the company's presentation of LentiGlobin sickle cell data at December's American Society of Hematology meeting remains underappreciated. The analyst, who notes the stock is up over 40% since Gilead's (GILD) acquisition of Kite Pharma (KITE) set off excitement about the CAR-T space that blue is also in, doesn't believe the ASH data will demonstrate the improvement in hemoglobin production necessary to increase confidence in sickle cell genetherapy, he tells investors. Harrison keeps a $105 price target on bluebird bio shares.
10/06/17
GSCO
10/06/17
INITIATION
Target $186
GSCO
Conviction Buy
bluebird bio reinstated with a Conviction Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on bluebird with a Conviction Buy and $186 price target due to its leading position in the highly innovative gene and dell therapy fields, with a focus on curative/corrective one-time treatment.
CRSP Crispr Therapeutics
$19.70

0.4 (2.07%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
07/13/17
RHCO
07/13/17
INITIATION
Target $16
RHCO
Hold
CRISPR Therapeutics initiated with a Hold at SunTrust
SunTrust analyst Peter Larson initiated CRISPR Therapeutics with a Hold and a $16 price target.
03/28/17
CHDN
03/28/17
INITIATION
Target $23.5
CHDN
Buy
CRISPR Therapeutics initiated with a Buy at Chardan
Chardan analyst Madhu Kumar initiated CRISPR Therapeutics with a Buy and a $23.50 price target saying upside from clinical leadership in CRISPR therapy offsets any potential downside from its IP exposure.
ARWR Arrowhead
$4.36

0.11 (2.59%)

09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
Arrowhead upgraded to Outperform from Market Perform at William Blair
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform saying the company's analyst day highlighted a "broad" pipeline.
09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
William Blair upgrades Arrowhead with $6 fair value estimate
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform from Market Perform and raised her fair value estimate for the shares to $6 from $2. The stock closed Friday up 51c to $3.30. Last week's R&D day revealed the TRiM platform for developing novel RNA interference medicines and promised five investigational new drug or clinical trial application filings in 2018, Xu tells investors in a research note. The analyst highlights "versatility" of the company's TRiM platform for designing decorated RNAi drugs.
11/30/16
11/30/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Sell from Hold at Berenberg. 2. Arrowhead (ARWR) was downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Buy at Chardan, to Hold from Buy at Cantor, and to Market Perform from Outperform at William Blair. 3. W.R. Grace (GRA) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander noting the potential for a sharp drop in free cash flow conversion once its net operating loss carry-forwards are exploited. 4. Abaxis (ABAX) downgraded to Neutral from Buy at Northcoast. 5. Duluth Holdings (DLTH) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing the stock's recent rally and the possibility its valuation metrics have pushed beyond the levels he believes it can sustain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/03/17
WBLR
03/03/17
NO CHANGE
WBLR
HBV space to consolidate over next five years, says William Blair
William Blair analyst Y. Katherine Xu sees curing chronic hepatitis B virus infections as "the next frontier" after the success of hepatitis C treatments and believes the market for an HBV cure could be "similar in size to that of HCV," or $200B in cumulative global sales over a span of two decades. She expects consolidation of the HBV market over the next five years, much like what happened with the HCV market. Xu sees Spring Bank Pharmaceuticals (SBPH) and Arbutus (ABUS) as having the strongest data catalysts in 2017, followed by Assembly Biosciences (ASMB) and Arrowhead (ARWR). She has Outperform ratings on the first three stocks and a Market Perform rating on Arrowhead.
AGTC Applied Genetic
$4.05

0.05 (1.25%)

09/14/17
BMOC
09/14/17
NO CHANGE
BMOC
Applied Genetic price target lowered to $7 from $14 at BMO Capital
BMO Capital analyst Matthew Luchini cut his price target on Applied Genetic as he lowered the chances of success of its lead XLRS program to 40% from 70%. He lowered the program's chance of success due to what he sees as lack of impact on patients treated in the dose escalation portion of a trial. However, the analyst believes that new Phase I/II data due to be reported in late 2017 or early 2018 could "help unlock a roughly $750M peak sales opportunity." He keeps an Outperform rating on the shares.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $8
HCWC
Buy
H.C. Wainwright halves Applied Genetic target on timeline pushouts
H.C. Wainwright analyst Joseph Pantginis halved his price target for Applied Genetic Technologies to $8 from $16 following the company's 2017 results. Today's XLRS update should increase frustration because the timeline has been pushed out to approximately mid-2018 for the potential data, Pantginis tells investors in a research note. The analyst pushed out his projected launch year for XLRS and ACHM-B3 from 2022 to 2023. He reiterates a Buy rating on Applied Genetic.
03/15/17
RODM
03/15/17
INITIATION
Target $16
RODM
Buy
Applied Genetic initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Applied Genetic Technologies with a Buy rating and $16 price target. The analyst calls the company a leader in adeno-associated virus development.
09/14/17
CANT
09/14/17
NO CHANGE
Target $9
CANT
Neutral
Applied Genetic price target lowered to $9 from $15 at Cantor
Cantor Fitzgerald analyst Mara Goldstein lowered her price target for Applied Genetic Technologies to $9 and keeps a Neutral rating on the name following the company's Q4 results and business update. The analyst cites the slow clinical progression of the company's trials and the revelation that the XLRS trial may need additional patients and time to identify therapeutic activity for the lowered target. She sees a "lack of actionable clinical data" in the near-term.
VBLT VBL Therapeutics
$5.95

0.15 (2.59%)

11/29/16
ROTH
11/29/16
NO CHANGE
ROTH
VBL Therapeutics mentioned positively at Roth Capital
11/29/16
ROTH
11/29/16
NO CHANGE
Target $17
ROTH
Buy
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.
MGEN Miragen Therapeutics
$9.34

-0.1 (-1.06%)

02/21/17
WEDB
02/21/17
INITIATION
Target $19
WEDB
Outperform
Miragen Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos initiated Miragen Therapeutics with an Outperform and a $19 price target.
06/01/17
COWN
06/01/17
INITIATION
COWN
Outperform
Miragen Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Miragen Therapeutics with an Outperform saying it has a promising microRNA platform technology with two candidates MRG-106 for CTCL and MRG-201 for fibrotic conditions. He believes the ongoing/imminent CTCL and keloid clinical studies should generate value creating data catalysts regularly over the next 18 months.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$97.99

0.37 (0.38%)

18:12
10/18/17
10/18
18:12
10/18/17
18:12
Hot Stocks
SEC names JPMorgan exec Redfearn Director of Division of Trading and Markets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:10
10/18/17
10/18
18:10
10/18/17
18:10
Periodicals
Verizon targets spring start of delayed online TV service, Bloomberg says »

Verizon web TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:04
10/18/17
10/18
18:04
10/18/17
18:04
Hot Stocks
Steel Dynamics CEO optimistic conditions in place to benefit FY18 consumption »

CEO Mark Millet said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CE

Celanese

$104.03

-0.24 (-0.23%)

18:03
10/18/17
10/18
18:03
10/18/17
18:03
Earnings
Celanese increases price for acetyls and engineered materials products »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:01
10/18/17
10/18
18:01
10/18/17
18:01
Earnings
Steel Dynamics reports Q3 ex-items EPS 66c, consensus 66c »

Reports Q3 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

OPTT

Ocean Power

$2.00

0.56 (38.89%)

17:59
10/18/17
10/18
17:59
10/18/17
17:59
Syndicate
Ocean Power files to sell common stock in 'best efforts' offering »

No amount was provided.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

, TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

17:58
10/18/17
10/18
17:58
10/18/17
17:58
Periodicals
Japan regulators probing Toshiba reporting practices for FY16/17, Nikkei says »

Japan's Securities…

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$87.34

-0.42 (-0.48%)

17:53
10/18/17
10/18
17:53
10/18/17
17:53
Hot Stocks
Pinnacle West raises quarterly divided 6.1% to 69.5c per share »

Pinnacle West…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

GILD

Gilead

$80.01

-0.23 (-0.29%)

17:46
10/18/17
10/18
17:46
10/18/17
17:46
Hot Stocks
FDA grants regulatory approval to Kite's Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 26

    Oct

  • 06

    Nov

  • 12

    Feb

POT

Potash

$19.24

0.08 (0.42%)

, AGU

Agrium

$107.73

0.55 (0.51%)

17:37
10/18/17
10/18
17:37
10/18/17
17:37
Hot Stocks
Potash, Agrium: India approves proposed merger of equals transaction »

Potash Corporation of…

POT

Potash

$19.24

0.08 (0.42%)

AGU

Agrium

$107.73

0.55 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$160.85

1.9 (1.20%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Earnings
Valmont lowers FY17 adjusted EPS view to $6.90-$7.04 from $7.06, consensus $7.09 »

Annual guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NVO

Novo Nordisk

$50.13

0.82 (1.66%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Hot Stocks
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committe »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CHFS

CHF Solutions

$8.30

-0.69 (-7.68%)

17:35
10/18/17
10/18
17:35
10/18/17
17:35
Syndicate
Breaking Syndicate news story on CHF Solutions »

CHF Solutions files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VTGN

VistaGen Therapeutics

$1.31

0.04 (3.15%)

17:33
10/18/17
10/18
17:33
10/18/17
17:33
Syndicate
Breaking Syndicate news story on VistaGen Therapeutics »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

, URI

United Rentals

$144.32

0.98 (0.68%)

17:32
10/18/17
10/18
17:32
10/18/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

URI

United Rentals

$144.32

0.98 (0.68%)

KMI

Kinder Morgan

$18.58

-0.1 (-0.54%)

ADBE

Adobe

$153.00

2.62 (1.74%)

CNAT

Conatus

$5.15

0.05 (0.98%)

EBAY

eBay

$37.97

0.48 (1.28%)

HXL

Hexcel

$58.94

0.39 (0.67%)

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

PEGI

Pattern Energy

RXDX

Ignyta

$16.25

1.9 (13.24%)

HCA

HCA Healthcare

$77.45

0.63 (0.82%)

KLAC

KLA-Tencor

$108.09

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 26

    Oct

  • 06

    Nov

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    May

  • 16

    May

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

VMI

Valmont

$160.85

1.9 (1.20%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Earnings
Valmont reports Q3 adjusted EPS $1.56, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AGEN

Agenus

$4.71

0.04 (0.86%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Syndicate
Breaking Syndicate news story on Agenus »

Agenus files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PEGI

Pattern Energy

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Hot Stocks
Pattern Energy sees Q3 operating loss greater than Q316 »

On October 18, Pattern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

GE

General Electric

$23.12

-0.07 (-0.30%)

17:25
10/18/17
10/18
17:25
10/18/17
17:25
Periodicals
General Electric CEO cutting expenses, employees, WSJ reports »

General Electric's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

UNB

Union Bankshares

$47.10

-0.8 (-1.67%)

17:20
10/18/17
10/18
17:20
10/18/17
17:20
Hot Stocks
Union Bankshares sees Q418 charge of $3.2M on plan termination »

On October 18, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:19
10/18/17
10/18
17:19
10/18/17
17:19
Earnings
Oil States lowers Q3 revenue view to $164M from $165M-$185M, consensus $177.77M »

Oil States anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:18
10/18/17
10/18
17:18
10/18/17
17:18
Hot Stocks
American Express says on track to cut $1B in costs by end of the year »

Says on track to cut $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:16
10/18/17
10/18
17:16
10/18/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Oil States »

Oil States lowers Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:08
10/18/17
10/18
17:08
10/18/17
17:08
Hot Stocks
American Express says 'right time' for leadership transition »

Comments taken from Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

APRN

Blue Apron

$5.30

-0.08 (-1.49%)

17:06
10/18/17
10/18
17:06
10/18/17
17:06
Hot Stocks
Blue Apron to cut roughly 6% of total workforce, inclur roughly $3.5M in expense »

Blue Apron said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.